Close menu

April 27th, 2022 | 11:54 CEST

Where the sentiment is right: BioNTech, Defence Therapeutics, Amazon

  • Biotechnology
Photo credits:

If you want to sell air mattresses in November, you will not succeed even with huge discounts. It is a similar story when selecting stocks. In order to reap returns, investors need to assess the market and bet on the stocks that will be in demand in the near future. In the case of vaccine stocks, the air seemed to be out recently. But now, there are growing indications that more vaccine doses may be needed. We take a look at the sentiment of three stocks.

time to read: 4 minutes | Author: Nico Popp

Table of contents:

    BioNTech: What is still to come?

    On a one-year horizon, the BioNTech share has a return of only 1%. This is all the more remarkable because the share price has risen by more than 100% during this period. Recently, more and more people have been saying that the pandemic has run its course and that demand for vaccines would therefore decline. Although the new relaxed attitude is making itself felt in supermarkets and at other events in Germany these days, there are also new warning signals. A Pfizer-funded study shows that the current BioNTech vaccine's protective efficacy against hospitalizations is 85% within the first three months but drops to 55% after that. The findings could lead to more younger people reaching for the fourth vaccination.

    It was recently revealed that some vaccine doses were at risk of expiring this summer. Therefore, the new study situation is unlikely to generate additional sales for BioNTech. Looking ahead to the fall, however, demand could pick up again. An updated vaccine is expected then. Against the background of the then beginning cold season, the fourth prick would again be close at hand for many people. BioNTech's stock represents more than just a provider of Corona vaccines - mRNA technology is powerful and could also lead to breakthroughs in cancer. If so, BioNTech would finally have arrived in the biotech Olympus. Even if you ignore the price excesses of the past two years, the value remains in an upward trend. However, investors are not getting a bargain with the BioNTech share.

    Defence Therapeutics: Patented drug enhancer as a multi-tool

    Defence Therapeutics, on the other hand, is a different story. The biotech Company from Canada is also pursuing a platform approach and has several irons in the fire. The Company is working on antibody-drug conjugates (ADCs) and has presented impressive results. These ADCs are capable of amplifying active substances and delivering them directly into an affected cell. Defence Therapeutics' patented Accum™ technology is being used around vaccines against COVID-19 and HPV, as well as breast and skin cancer. Several Phase 1 studies are planned for this in the coming months. The conditions for a successful outcome appear favorable. "Such studies cost money. Given our encouraging results to date and the versatility of our technology, we are finding receptive ears in discussions with potential funders," said Dr. Moutih Rafei, Director and VP of Research and Development, Defence Therapeutics, in an interview.

    Even without agents associated with Accum™, the technology appears potent: "Accum™ is very toxic. We found that cancer cells die when we inject the drug directly into tumors. At the same time, Accum™ provides synergistic effects with other existing therapies. Specifically, this means that Accum™ is effective against cancer cells on the one hand but also supports other known active ingredients on the other. Possible application areas include breast cancer and previously incurable brain tumors, so-called glioblastomas. The only important thing is that Accum™ can be injected directly into the tumors. There are already experts who can use active substances in such a targeted manner. However, we are still a long way from a concrete application of Accum™ in this way," says Rafei. Initially, however, Defence Therapeutics intends to focus on patients with breast and skin cancer. Collaborations with clinics are already in place for this purpose. Most recently, the Company also obtained another patent that provides additional protection for the use of Accum™ around vaccines. This should also reduce the risk of competitors copying the approach and increase the likelihood that the Company will find cooperation partners around individual areas of application or license its technology. The stock has come back in a similar fashion to BioNTech but is still in solid charting waters. Due to the Company's relative unfamiliarity and the fact that it has not yet reached market maturity, the risk-reward profile is much more pronounced.

    Amazon: This success is timeless

    When it comes to buying stocks that are booming right now, the Amazon share cannot be missed. While some pandemic stocks, such as Peloton or even Netflix, have recently gone under the wheels, Amazon has held comparatively steady. The reason: the business model works even after the pandemic. More and more people were already shopping online in 2019, and the pandemic has only strengthened the trend. Part of the pandemic exaggeration has been relieved by Amazon, which is now hovering between USD 2,500 and USD 3,000. The lower end of this range could offer interesting opportunities. There are many reasons for the stock: in addition to the timeless business model, the weakness of competitor Netflix could also be an argument for Amazon.

    Whether biotech or retail, both sectors have a future, as long as entry into the respective shares is not too expensive. Timing always becomes a challenge when share prices are already pricing in a rosy future. That is most likely the case with BioNTech. As a market leader, Amazon is, of course, not cheap either. On the other hand, investors can seize opportunities in second-tier stocks that the market has not yet given an advance. One example of such a company is Defence Therapeutics.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Nico Popp on February 2nd, 2023 | 18:04 CET

    Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?

    • Biotechnology
    • Cannabis
    • Cancer

    He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?


    Commented by Stefan Feulner on February 1st, 2023 | 20:29 CET

    BioNTech, Defence Therapeutics, PAION - All dams broken

    • Biotechnology

    High price fluctuations due to approvals or successful test results are more the norm than the rule in the biotechnology sector. It is common for smaller stocks, in particular, to multiply within a few days. For example, the shares of Ambrx Biopharma increased by a whopping 1,000% within just one day, while the German biotech hopeful PAION doubled in price within a week. The next candidates for above-average performances are already waiting in the wings.


    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?